Related Experiment Video
Updated: Mar 17, 2026
07:17
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
1.9K
Gastrointestinal Non-Hodgkin's Lymphoma
A K Stewart1, F A Shepherd1, P E Goss1
1a Departments of Medicine, University of Toronto, Toronto, Ontario, Canada.
Leukemia & Lymphoma
|July 27, 2016
Summary
Stage at diagnosis is the key factor for gastrointestinal Non-Hodgkin's Lymphoma (GI-NHL) survival. Early stage GI-NHL patients benefit from complete surgical resection, improving prognosis.
Area of Science:
- Oncology
- Gastroenterology
- Hematology
Background:
- Gastrointestinal Non-Hodgkin's Lymphoma (GI-NHL) is a rare malignancy with varied clinical presentations.
- Understanding prognostic factors is crucial for optimizing treatment strategies in GI-NHL.
Purpose of the Study:
- To analyze survival outcomes and prognostic factors in a cohort of patients with GI-NHL.
- To evaluate the impact of disease stage, treatment modalities, and patient characteristics on survival.
Main Methods:
- Retrospective review of 77 GI-NHL patient records diagnosed between 1972 and 1988.
- Analysis of patient demographics, disease stage, primary site, histology, treatment received, and survival data.
- Statistical correlation of prognostic factors with patient survival.
Main Results:
- Disease stage at presentation was the strongest predictor of survival (p = 0.003).
- Complete surgical resection significantly improved survival for stage I and II GI-NHL patients (p = 0.003).
- Chemotherapy resulted in complete remission in 56% and partial remission in 32% of patients with evaluable disease.
Conclusions:
- Early stage (I and II) GI-NHL with complete surgical resection offers the best prognosis.
- Advanced stage GI-NHL (III and IV) has a poorer prognosis, with surgery not significantly altering survival.
- Disease stage is the most critical determinant of long-term survival in GI-NHL.
